Compile Data Set for Download or QSAR
Report error Found 11 Enz. Inhib. hit(s) with all data for entry = 10426
TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340036BDBM340036(US9758508, Compound 17 | 1-(3-chloro-2,6-difluorop...)
Affinity DataIC50: 0.0500nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340037BDBM340037(US9758508, Compound 18 | 1-(2-chloro-3,6-difluorop...)
Affinity DataIC50: 0.0700nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340031BDBM340031(US9758508, Compound 7 | 1-{3-fluoro-4-[7-(5-methyl...)
Affinity DataIC50: 0.100nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340033BDBM340033(US9758508, Compound 12 | 1-{3-fluoro-4-[7-(5-methy...)
Affinity DataIC50: 0.280nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340032BDBM340032(US9758508, Compound 9 | 1-{3-fluoro-4-[7-(5-methyl...)
Affinity DataIC50: 0.400nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340030BDBM340030(US9758508, Compound 4 | 1-(2-chloro-6-fluoro-pheny...)
Affinity DataIC50: 0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340039BDBM340039(US9758508, Compound 20 | 1-{3-fluoro-4-[7-(5-methy...)
Affinity DataIC50: 0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340029BDBM340029(US9758508, Compound 3 | 1-(2,6-difluoro-phenyl)-3-...)
Affinity DataIC50: 1nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340038BDBM340038(US9758508, Compound 19 | 1-(4-chloro-2,6-difluoro-...)
Affinity DataIC50: 4nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340035BDBM340035(US9758508, Compound 15 | 1-(4-cyano-3-fluorophenyl...)
Affinity DataIC50: 5nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Crystalgenomics

US Patent
LigandChemical structure of BindingDB Monomer ID 340034BDBM340034(US9758508, Compound 14 | 1-(3,4-difluoro-phenyl)-3...)
Affinity DataIC50: 5.60nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/30/2022
Entry Details
US Patent